Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.66 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | CA9 | Q16790 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27880557 | 0.94 | CA12 (0.60) | CA12CA1CA2CA9LMNA | |
| SCHEMBL11651843 | 0.94 | CA12 (0.60) | CA12CA1CA2CA9LMNA | |
| SCHEMBL28433159 | 0.92 | CA12 (0.63) | CA12CA1CA2CA9LMNA | |
| SCHEMBL9673742 | 0.90 | ALDH1A1 (0.63) | CA12CA1CA2CA9LMNA | |
| SCHEMBL7356625 | 0.90 | SMN1; SMN2 (0.60) | CA12CA1CA2CA9LMNA | |
| SCHEMBL28954497 | 0.90 | ALDH1A1 (0.63) | CA12CA1CA2CA9LMNA | |
| SCHEMBL2918702 | 0.90 | GAA (0.64) | CA12CA1CA2CA9LMNA | |
| SCHEMBL234454 | 0.89 | LMNA (0.62) | CA12CA1CA2CA9LMNA | |
| SCHEMBL4149248 | 0.88 | ALDH1A1 (0.60) | CA12CA1CA2CA9LMNA | |
| SCHEMBL12832074 | 0.87 | CA12 (0.54) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005028449-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF 1,2-DISUBSTITUTED HEXAHYDROPYRIDAZINE-3-CARBOXYLIC ACIDS AND ESTERS THEREOF | HONEYWELL SPECIALTY CHEMICALS SEELZE GMBH (DE) | 2005-03-31 | — | — | WO | claimed |
| CN-119936220-A | Detection method of diamine impurity, minocycline hydrochloride capsule and preparation method | 海口市制药厂有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-111494395-B | Carbidopa and levodopa prodrugs and their use for treating parkinson's disease | 艾伯维公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-112409253-B | Method for synthesizing chiral alpha-tertiary amine by catalytic kinetic resolution | 上海科技大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-111393333-B | Preparation method of 4-amino substituted cyclohexadienone derivative | 武汉英纳氏药业有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-106132984-A | Pharmaceutically-related aromatic-cationic peptides | 康德生物医疗技术公司 | 2016-11-16 | — | — | CN | disclosed |
| US-8901119-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-12-02 | — | — | US | disclosed |
| US-8901119-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-12-02 | — | — | US | disclosed |
| US-8901119-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-12-02 | — | — | US | disclosed |
| US-20130345120-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| CN-101282976-A | Xanthine derivatives as selective HM74A agonists | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| US-7132535-B2 | Process for preparing hexahydropyridazine-3-carboxylic acid derivatives | ISOCHEM (FR) | 2006-11-07 | — | — | US | disclosed |
| EP-1468993-B1 | Process for the preparation of hexahydropyridazine-3-carboxylic acid derivatives | ISOCHEM SA (FR) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005028449-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF 1,2-DISUBSTITUTED HEXAHYDROPYRIDAZINE-3-CARBOXYLIC ACIDS AND ESTERS THEREOF | HONEYWELL SPECIALTY CHEMICALS SEELZE GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
| US-20040210053-A1 | Process for preparing hexahydropyridazine-3-carboxylic acid derivatives | ISOCHEM (FR) | 2004-10-21 | — | — | US | disclosed |
| EP-1468993-A1 | Process for the preparation of hexahydropyridazine-3-carboxylic acid derivatives | ISOCHEM (FR) | 2004-10-20 | — | — | EP | disclosed |
| US-20030130269-A1 | Derivatives of octahydro-6, 10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds | AVENTIS PHARMA S.A. | 2003-07-10 | — | — | US | disclosed |
| US-6570012-B2 | Derivatives of octahydro-6, 10-dioxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid, useful for preperation of therapeutically active compounds | AVENTIS PHARMA S.A. (FR) | 2003-05-27 | — | — | US | disclosed |
| US-6548664-B1 | Alkylation, hydrogenation, cyclization, condensation, deracemization | AVENTIS PHARMA S.A. (FR) | 2003-04-15 | — | — | US | disclosed |
| US-20020128473-A1 | Derivatives of octahydro-6,10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds | AVENTIS PHARMA S.A. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130269-A1 | Derivatives of octahydro-6, 10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds | CYP2S1, DEGS1, GRIK1 | CA12 3824/4885CA1 2012/4885CA2 2423/4885 |
| US-20040210053-A1 | Process for preparing hexahydropyridazine-3-carboxylic acid derivatives | CYP3A5, HK1, HK2 | CA12 668/4885CA1 539/4885CA2 273/4885 |
| US-20020128473-A1 | Derivatives of octahydro-6,10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds | CYP2D6, THPO, CYP2B6 | CA12 2934/4885CA1 1260/4885CA2 2553/4885 |
| US-20130345120-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, PEPD, VIP | CA12 4826/4885CA1 4820/4885CA2 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.